Ferret coronavirus-associated diseases

Veterinary Clinics of North America - Exotic Animal Practice

Volumn 13, Issue 3, 2010, Pages 543-560

  Murray, Jerry ^a   Kiupel, Matti ^b   Maes, Roger K ^c  

^a Animal Clinic of Farmers Branch   (United States)

^b MICHIGAN STATE UNIVERSITY   (United States)

^c NONE   (United States)

Author keywords

Coronavirus; Feline infectious peritonitis; Ferret; Granuloma; Hypergammaglobulinemia; Mustela putorius furo

Indexed keywords

ANIMAL; CORONAVIRUS; CORONAVIRUS INFECTIONS; ENTERITIS; FEMALE; FERRET; ISOLATION AND PURIFICATION; MALE; VETERINARY; VIROLOGY;

ANIMALS; CORONAVIRUS; CORONAVIRUS INFECTIONS; ENTERITIS; FEMALE; FERRETS; MALE;

EID: 77955242478     PISSN: 10949194     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cvex.2010.05.010     Document Type: Review

References (83)

1. Lai M.M.C., Perlman S., Anderson L.J. Coronaviridae. Fields virology 2007, 1305-1335. Lippincott Williams & Wilkins, Philadelphia. 5th edition. D.M. Knipe, P.M. Howley (Eds.).
2. Gonzalez J.M., Gomez-Puertas P., Cavanagh D., et al. A comparative sequence analysis to revise the current taxonomy of the family Coronaviridae. Arch Virol 2003, 148(11):2207-2235.
3. Wise A.G., Kiupel M., Maes R.K. Molecular characterization of a novel coronavirus associated with epizootic catarrhal enteritis (ECE) in ferrets. Virology 2006, 349(1):164-174.
4. Wise A., Kiupel M., Garner M.M., et al. Comparative sequence analysis of the distal one-third of the genomes of a systemic and an enteric ferret coronavirus. Virus Res 2010, 149(1):42-50.
5. Williams B., Kiupel M., West K., et al. Coronavirus associated epizootic catarrhal enteritis in ferrets. J Am Vet Med Assoc 2000, 217(4):526-530.
6. Martinez J., Ramis A.J., Reinacher M., et al. Detection of feline infectious peritonitis virus-like antigen in ferrets. Vet Rec 2006, 158(15):523.
7. Garner M.M., Ramsell K., Morera N., et al. Clinicopathologic features of a systemic coronavirus-associated disease resembling feline infectious peritonitis in the domestic ferret (Mustela putorius). Vet Pathol 2008, 45(2):236-246.
8. Juan-Salles C., Teifke J.P., Morera N., et al. Pathology and immunohistochemistry of a disease resembling feline infectious peritonitis in ferrets (Mustela putorius furo). Vet Pathol 2006, 43(5):845.
9. Rottier P.J.M., Nakamura K., Schellen P., et al. Acquisition of macrophage tropism during the pathogenesis of feline infectious peritonitis is determined by mutations in the feline coronavirus spike protein. J Virol 2005, 79:14122-14130.
10. Brown M.A., Troyer J.L., Pecon-Slattery J., et al. Genetics and pathogenesis of feline infectious peritonitis virus. Emerg Infect Dis 2009, 15(9):1445-1452.
11. Martínez J., Reinacher M., Perpiñán D., et al. Identification of group 1 coronavirus antigen in multisystemic granulomatous lesions in ferrets (Mustela putorius furo). J Comp Pathol 2008, 138:54-58.
12. Hartmann K. Feline infectious peritonitis. Vet Clin North Am Small Anim Pract 2005, 35:39-79.
13. Pedersen N.C. A review of feline infectious peritonitis virus infection: 1963-2008. J Feline Med Surg 2009, 11:225-258.
14. Perpinan D., Lopez C. Clinical aspects of systemic granulomatous inflammatory syndrome in ferrets (Mustela putorius furo). Vet Rec 2008, 162(6):180-183.
15. Weiss R.C., Scott F.W. Pathogenesis of feline infectious peritonitis: pathologic changes and immunofluorescence. Am J Vet Res 1981, 42:2036-2048.
16. Murray J. Clinical management of systemic coronavirus in domestic ferrets. In: Proceedings of the 29th Annual AAV Conference & Expo with AEMV. Savannah (GA), August 11-14, 2008. p. 51-5.
17. Ramsell KD, Garner MM, Maes R, et al. A disease resembling feline infectious peritonitis in the domestic ferret. In: Proceedings of the International Ferret Symposium. Portland, June 22-24, 2007.
18. Garner M.M. Focus on diseases of ferrets. Exotic DVM 2003, 5(3):75-80.
19. Addie D., Belak S., Boucraut-Baralon C., et al. Feline infectious peritonitis. ABCD guidelines on prevention and management. J Feline Med Surg 2009, 11:594-604.
20. Simons F.A., Vennema H., Rofina J.E., et al. A mRNA PCR for the diagnosis of feline infectious peritonitis. J Virol Methods 2005, 124:111-116.
21. Tizard I. Drugs that affect the immune system. Veterinary immunology 1992, 447-456. WB Saunders, Philadelphia. 4th edition.
22. Gregory C.R. Immunosuppressive agents. Kirk's current veterinary therapy XIII 2000, 509-513. WB Saunders, Philadelphia. J.D. Bonagura (Ed.).
23. Taylor H.G., Samanta A. Treatment of vasculitis. Br J Clin Pharmacol 1993, 35:93-104.
24. Addie D.D., Ishida T. Feline infectious peritonitis: therapy and prevention. Kirk's current veterinary therapy XIV 2009, 1295-1298. Saunders Elsevier, St Louis (MO). J.D. Bonagura, D.C. Twedt (Eds.).
25. Hartmann K. Diagnosis and treatment of feline infectious peritonitis. Consultations in feline internal medicine 2010, vol. 6:62-76. Saunders Elsevier, St. Louis (MO). J.R. August (Ed.).
26. Addie D.D., Jarett O. Feline coronavirus infections. Infectious diseases of the dog and cat 2006, 88-102. Saunders Elsevier, St Louis (MO). 3rd edition. C.E. Greene (Ed.).
27. Jones C.J.P., Morris K.J., Jayson M.I.V. Prednisolone inhibits phagocytosis by polymorphonuclear leucocytes via steroid receptor mediated events. Ann Rheum Dis 1983, 42(1):56-62.
28. Legendre A.M., Bartges J.W. Effect of polyprenol immunostimulant on the survival times of three cats with the dry form of feline infectious peritonitis. J Feline Med Surg 2009, 11(8):624-626.
29. Weiss R.C., Cox N.R., Oostrom-Ram T. Effect of interferon or Propionibacterium acnes on the course of experimentally induced feline infectious peritonitis in specific-pathogen-free and random-source cats. Am J Vet Res 1990, 51(5):726-733.
30. Ishida T., Shibanai A., Tanaka S., et al. Use of recombinant feline interferon and glucocorticoid in the treatment of feline infectious peritonitis. J Feline Med Surg 2004, 6(2):107-109.
31. Ritz S., Egberink H., Hartmann K. Effect of feline interferon-omega on the survival times and quality of life of cats with feline infectious peritonitis. J Vet Intern Med 2007, 21(6):1193-1197.
32. Kennedy M.A. An update on feline infectious peritonitis. Vet Med 2009, 104(8):384-391.
33. Kipar A., May H., Menger S., et al. Morphologic features and development of granulomatous vasculitis in feline infectious peritonitis. Vet Pathol 2005, 42(3):321-330.
34. Marsella R. Pentoxifylline. Kirk's current therapy XIV 2009, 397-400. Saunders Elsevier, St Louis (MO). J.D. Bonagura, D.C. Twedt (Eds.).
35. Scott D.W., Miller W.H., Griffin C.E. Dermatologic therapy. Muller & Kirk's small animal dermatology 2001, 241. WB Saunders, Philadelphia. 6th edition.
36. Mendes J.B., Campos P.P., Rocha M.A., et al. Cilostazol and pentoxifylline decrease angiogenesis, inflammation, and fibrosis in sponge-induced intraperitoneal adhesion in mice. Life Sci 2009, 84(15-16):537-543.
37. Deree J., Lall R., Melbostad H., et al. Neutrophil degranulation and effects of phosphodiesterase inhibition. J Surg Res 2006, 133(1):22-28.
38. Scott D.W., Miller W.H., Griffin C.E. Immune-mediated disorders. Muller & Kirk's small animal dermatology 2001, 742-756. WB Saunders, Philadelphia. 6th edition.
39. Fernandes J.L., de Oliveira R.T., Mamoni R.L., et al. Pentoxifylline reduces pro-inflammatory and increases anti-inflammatory activity in patients with coronary artery disease-a randomized placebo-controlled study. Atherosclerosis 2008, 196(1):434-442.
40. Duman D.G., Ozdemir F., Birben E., et al. Effects of pentoxifylline on TNF-alpha production by peripheral blood mononuclear cells in patients with nonalcoholic steatohepatitis. Dig Dis Sci 2007, 52(10):2520-2524.
41. Satapathy S.K., Sakhuja P., Malhotra V., et al. Beneficial effects of pentoxifylline on hepatic steatosis, fibrosis and necroinflammation in patients with non-alcoholic steatohepatitis. J Gastroenterol Hepatol 2007, 22(5):634-638.
42. Maiti R., Agrawai N.K., Dash D., et al. Effect of pentoxifylline on inflammatory burden, oxidative stress and platelet aggregability in hypertensive type 2 diabetes mellitus patients. Vascul Pharmacol 2007, 47(2-3):118-124.
43. Raffetto J.D., Khalil R.A. Matrix metalloproteinases and their inhibitors in vascular remoldeling and vascular disease. Biochem Pharmacol 2008, 75(2):346-359.
44. Mulivor A.W., Lipowsky H.H. Inhibition of glycan shedding and leukocyte-endothelial adhesion in postcapillary venules by suppression of matrixmetalloprotease activity with doxycycline. Microcirculation 2009, 4:1-10.
45. Liu J., Xiong W., Baca-Regen L., et al. Mechanism of inhibition of matrix metalloproteinase-2 expression by doxycycline in human aortic smooth muscle cells. J Vasc Surg 2003, 38(6):1376-1383.
46. Hackmann A.E., Rubin B.G., Sanchez L.A., et al. A randomized, placebo-controlled trial of doxycycline after endoluminal aneurysm repair. J Vasc Surg 2008, 48(3):519-526.
47. Iovieno A., Lambiase A., Micera A., et al. In vivo characterization of doxycycline effects on tear metalloproteinases in patients with chronic blepharitis. Eur J Ophthalmol 2009, 19(5):708-716.
48. Lee H.M., Ciancio S.G., Tuter G., et al. Subantimicrobial dose doxycycline efficacy as a matrix metalloproteinase inhibitor in chronic periodontitis patients is enhanced when combined with a non-steroidal anti-inflammatory drug. J Periodontal 2004, 75(3):453-463.
49. Gu Y., Lee H.M., Sorsa T., et al. Doxycycline inhibits mononuclear cell-mediated connective tissue breakdown. FEMS Immunol Med Microbiol 2010, 58(2):218-225.
50. Lau A.C., Duong T.T., Ito S., et al. Inhibition of matrix metalloproteinase-9 activity improves coronary outcome in an animal model of Kawasaki disease. Clin Exp Immunol 2009, 157(2):300-309.
51. Hori Y., Kunihiro S., Sato S., et al. Doxycycline attenuates isoproterenol-induced mycocardial fibrosis and matrix metalloproteinase activity in rats. Biol Pharm Bull 2009, 32(10):1678-1682.
52. Lewington J.H. Diseases of the ferret ear, eye and nose. Ferret husbandry, medicine and surgery 2007, 311. Saunders Elsevier, Sydney (Australia). 2nd edition.
53. Watari T., Kaneshima T., Tsujikoto H., et al. Effect of thromboxane synthetase inhibitor on feline infectious peritonitis in cats. J Vet Med Sci 1998, 60(5):657-659.
54. Moraes L.A., Paul-Clark M.J., Rickman A., et al. Ligand-specific glucocorticoid receptor activation in human platelets. Blood 2005, 106(13):4167-4175.
55. Debets J.M., Ruers T.J., van der Linden M.P., et al. Inhibitory effect of corticosteroids on the secretion of tumor necrosis factor (TNF) by monocytes is dependant on the stimulus inducing TNF synthesis. Clin Exp Immunol 1989, 78(2):224-229.
56. Williams B.H. Therapeutics in ferrets. Vet Clin North Am Exot Anim Pract 2000, 3(1):131-153.
57. Antinoff N., Hahn K. Ferret oncology: diseases, diagnostics, and therapeutics. Vet Clin North Am Exot Anim Pract 2004, 7(3):579-625.
58. Bourinbalar A.S., Fruhstorfer E.C. The effect of histamine type 2 receptor antagonists on human immunodeficiency virus (HIV) replication: identification of a new class of antiviral agents. Life Sci 1996, 59(23):365-370.
59. Kabuta H., Yamamoto S., Shingu M. The effect of cimetidine on survival of mice infected with herpes simplex virus type 2, murine encephalomyelitis and vesicular stomatitis virus infections. Kurume Med J 1989, 36(3):95-99.
60. Hirai N., Hill N.O., Motoo Y., et al. Antiviral and antiproliferative activities of human leukocyte interferon potentiated by cimetidine in vitro. J Interferon Res 1985, 5(3):375-382.
61. Nishiguchi S., Tamori A., Shiomi S., et al. Cimetidine reduces impairment of cellular immunity after transcatheter arterial embolization in patients with hepatocellular carcinoma. Hepatogastroenterology 2003, 50(50):460-462.
62. Katoh J., Tauchiya K., Osawa H., et al. Cimetidine reduces impairment of cellular immunity after cardiac operations with cardiopulmonary bypass. J Thorac Cardiovasc Surg 1998, 116(2):312-318.
63. Powers L.V. Bacterial and parasitic diseases of ferrets. Vet Clin North Am Exot Anim Pract 2009, 12(3):531-561.
64. Hoppes S, Xenoulis PG, Berghoff N, et al. Serum cobalamin, folate, and methylmalonic acid concentrations in ferrets (Mustela putorius). In: Proceedings of the 29th Annual AAV Conference & Expo with AEMV. Savannah (GA), August 11-14, 2008. p. 61-3.
65. Reiter R.J., Melchiorri D., Sewerynek E., et al. A review of the evidence supporting melatonin's role as an antioxidant. J Pineal Res 1995, 18(1):1-11.
66. Reiter R.J., Tan D.X., Gitto E., et al. Pharmacological utility of melatonin in reducing oxidative cellular and molecular damage. Pol J Pharmacol 2004, 56(2):158-170.
67. Zararsiz I., Sarsilmaz W., Tas U., et al. Protective effects of melatonin against formaldehyde-induce kidney damage in rats. Toxicol Ind Health 2007, 23(10):573-579.
68. Maldonado M.D., Mora-Santos M., Naji L., et al. Evidence of melatonin synthesis and release by mast cells. Possible modulatory role on inflammation. Pharmacol Res 2009 Dec 3, [Epub ahead of print].
69. Lahiri S., Singh P., Singh S., et al. Melatonin protects against experimental reflux esophagitis. J Pineal Res 2009, 46(2):207-213.
70. Ganguly K., Swamaker S. Induction of matrix metalloproteinase-9 and -3 in nonsteroidal anti-inflammatory drug-induced acute gastric ulcers in mice: regulation by melatonin. J Pineal Res 2009, 47(1):43-55.
71. Swamaker S., Mishra A., Ganguly K., et al. Matrix metalloproteinase-9 activity and expression is reduced by melatonin during prevention of ethanol-induced gastric ulcer in mice. J Pineal Res 2007, 43(10):56-64.
72. Hung Y.C., Chen T.Y., Lee E.J., et al. Melatonin decreases matrix metalloproteinase-9 activation and expression and attenuates reperfusion-induced hemorrhage following transient focal cerebral ischemia in rats. J Pineal Res 2008, 45(4):459-467.
73. Esposito E., Mazzon E., Riccardi L., et al. Matrix metalloproteinase-9 and metalloproteinase-2 activity and expression is reduced by melatonin during experimental colitis. J Pineal Res 2008, 45(2):166-173.
74. Srinivasan V., Spence D.W., Trakht I., et al. Immunomodulation by melatonin: its significance for seasonally occurring diseases. Neuroimmunomodulation 2008, 15(2):93-101.
75. Reiter R.J., Calvo J.R., Karbownik M., et al. Melatonin and its relation to the immune system and inflammation. Ann N Y Acad Sci 2000, 917:376-386.
76. Maestroni G.J. Therapeutic potential of melatonin in immunodeficiency states, viral diseases, and cancer. Adv Exp Med Biol 1999, 467:217-226.
77. Bonilla E., Valero N., Chacin-Bonilla L., et al. Melatonin and viral infections. J Pineal Res 2004, 36(2):73-79.
78. Huang S.H., Cao X.J., Wei W. Melatonin decreases TLR3-mediated inflammatory factor expression via inhibition of NF-kappa B activation in respiratory syncytial virus-infected RAW264.7 macrophages. J Pineal Res 2008, 45(1):93-100.
79. Nunes O.S., Pereira R.S. Regression of herpes viral infection symptoms using melatonin and SB-73: comparison with acyclovir. J Pineal Res 2008, 44(4):373-378.
80. Webb C.B., Lehman T.L., McCord K.W. Effects of an oral superoxide dismutase enzyme supplementation on indices of oxidative stress, proviral load, and CD4:CD8 ratios in asymptomatic FIV-infected cats. J Feline Med Surg 2008, 10(5):423-430.
81. Webster C.R., Cooper J. Therapeutic use of cytoprotective agents in canine and feline hepatobiliary disease. Vet Clin North Am Small Anim Pract 2009, 39(3):631-652.
82. Gisselman K., Langston C., Palma D., et al. Calcium oxalate urolithiasis. Compend Contin Educ Pract Vet 2009, 31(11):496-500.
83. Osborne C.A., Albasan H., Lulich J.P., et al. Quantitative analysis of 4468 uroliths retrieved from farm animals, exotic species, and wildlife submitted to the Minnesota Urolith center: 1981-2007. Vet Clin North Am Small Anim Pract 2008, 39:65-78.